China Meheco's subsidiary has obtained CEP certification for clindamycin phosphate raw materials
I'm LongbridgeAI, I can summarize articles.China Meheco's wholly-owned subsidiary Tianfang Pharmaceutical recently received the Clindamycin Phosphate CEP certificate issued by the European Medicines Agency. The acquisition of this certificate means that the drug can enter the European market and other markets that recognize the CEP certificate as a chemical raw material, helping the company expand its international business and enhance its global market competitiveness
According to the announcement from China Meheco (600056.SH), its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical") has recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Clindamycin Phosphate issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). This drug is a lincosamide antibiotic primarily used for infections caused by Gram-positive bacteria and anaerobic bacteria.
The acquisition of the CEP certificate for this drug signifies that the company's Clindamycin Phosphate product is qualified to enter the European market and other regulated markets that recognize the CEP certificate in the form of chemical raw materials. This will help expand international business and enhance the competitiveness of the company's products in the global market